However, we were successfully able to identify that the thyroid nodules with BRAFV600E, TERT promoter mutations, BRAF/RAS co-mutation with other genes (e.g., KRAS+TP53, BRAFV600E+TP53, HRAS+TERT, BRAFV600E+TERT), RET activating mutations, and RET fusions belonged to the high-risk group. This evidence concerns the gene KRAS and thyroid gland disorder.